Alec A Schmaier1, Paurush Ambesh2, Umberto Campia3. 1. Brigham & Women's Hospital, 75 Francis St. AB378, Boston, MA, 02115, USA. 2. Maimonides Medical Center, Department of Internal Medicine, 4802 10th Ave, Brooklyn, NY, 11219, USA. 3. Brigham & Women's Hospital, 75 Francis St. AB378, Boston, MA, 02115, USA. ucampia@bwh.harvard.edu.
Abstract
PURPOSE OF REVIEW: This review aims to summarize the epidemiology, current pathophysiologic understanding, and state-of-the-art treatment of venous thromboembolism (VTE) in cancer patients. RECENT FINDINGS: The risk of VTE varies among cancer patients. Recently introduced prediction models better identify those at high risk of VTE. New mechanisms underlying hypercoagulability in cancer have been uncovered. Initial data on the efficacy of direct oral anticoagulants (DOACs) compared with low-molecular weight heparin to treat VTE in patients with cancer are promising. However, they may be associated with higher risk of gastrointestinal bleeding. VTE causes significant morbidity and mortality in cancer patients. Our understanding of the mechanisms of VTE, including those associated with cancer treatments, has significantly grown. The assessment of the benefit/risk balance of VTE treatment remains challenging in many patients with cancer. The introduction of DOACs has expanded treatment options, but knowledge on their efficacy and safety is incomplete.
PURPOSE OF REVIEW: This review aims to summarize the epidemiology, current pathophysiologic understanding, and state-of-the-art treatment of venous thromboembolism (VTE) in cancerpatients. RECENT FINDINGS: The risk of VTE varies among cancerpatients. Recently introduced prediction models better identify those at high risk of VTE. New mechanisms underlying hypercoagulability in cancer have been uncovered. Initial data on the efficacy of direct oral anticoagulants (DOACs) compared with low-molecular weight heparin to treat VTE in patients with cancer are promising. However, they may be associated with higher risk of gastrointestinal bleeding. VTE causes significant morbidity and mortality in cancerpatients. Our understanding of the mechanisms of VTE, including those associated with cancer treatments, has significantly grown. The assessment of the benefit/risk balance of VTE treatment remains challenging in many patients with cancer. The introduction of DOACs has expanded treatment options, but knowledge on their efficacy and safety is incomplete.
Authors: J R Perry; J A Julian; N J Laperriere; W Geerts; G Agnelli; L R Rogers; M G Malkin; R Sawaya; R Baker; A Falanga; S Parpia; T Finch; M N Levine Journal: J Thromb Haemost Date: 2010-09 Impact factor: 5.824
Authors: C W Francis; C M Kessler; S Z Goldhaber; M J Kovacs; M Monreal; M V Huisman; D Bergqvist; A G Turpie; T L Ortel; A C Spyropoulos; I Pabinger; A K Kakkar Journal: J Thromb Haemost Date: 2015-05-10 Impact factor: 5.824
Authors: A S Savchenko; K Martinod; M A Seidman; S L Wong; J I Borissoff; G Piazza; P Libby; S Z Goldhaber; R N Mitchell; D D Wagner Journal: J Thromb Haemost Date: 2014-06 Impact factor: 5.824
Authors: C Font; B Farrús; L Vidal; T M Caralt; L Visa; B Mellado; D Tàssies; J Monteagudo; J C Reverter; P Gascon Journal: Ann Oncol Date: 2011-02-16 Impact factor: 32.976
Authors: Martha L Louzada; Marc Carrier; Alejandro Lazo-Langner; Vi Dao; Michael J Kovacs; Timothy O Ramsay; Marc A Rodger; Jerry Zhang; Agnes Y Y Lee; Guy Meyer; Philip S Wells Journal: Circulation Date: 2012-06-07 Impact factor: 29.690
Authors: Agnes Y Y Lee; Pieter W Kamphuisen; Guy Meyer; Rupert Bauersachs; Mette S Janas; Mikala F Jarner; Alok A Khorana Journal: JAMA Date: 2015-08-18 Impact factor: 56.272
Authors: Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami Journal: Blood Date: 2002-07-12 Impact factor: 22.113